Integrated Biobank of Luxembourg
6
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Personalized Functional Profiling in Metastatic Gastrointestinal Cancer or Recurrent Glioblastoma Patients in Luxembourg.
Role: collaborator
Biomarkers in Food Allergy Diagnosis
Role: collaborator
Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest
Role: collaborator
Luxembourgish Fiber Cohort
Role: collaborator
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy
Role: collaborator
Biomarker Discovery and Validation in Lung Cancer
Role: collaborator
All 6 trials loaded